Omeros (NASDAQ:OMER) Stock Rating Lowered by StockNews.com

StockNews.com lowered shares of Omeros (NASDAQ:OMER) from a hold rating to a sell rating in a research note released on Tuesday morning.

Omeros Price Performance

Shares of Omeros stock opened at $4.26 on Tuesday. Omeros has a 12 month low of $1.17 and a 12 month high of $5.68. The stock has a market capitalization of $246.85 million, a P/E ratio of -1.81 and a beta of 1.47. The business has a 50 day simple moving average of $4.01 and a two-hundred day simple moving average of $4.04.

Hedge Funds Weigh In On Omeros

Hedge funds and other institutional investors have recently modified their holdings of the business. Susquehanna Fundamental Investments LLC purchased a new position in Omeros in the 1st quarter worth approximately $538,000. BNP Paribas Financial Markets increased its stake in shares of Omeros by 75.5% in the 1st quarter. BNP Paribas Financial Markets now owns 30,102 shares of the biopharmaceutical company’s stock worth $104,000 after acquiring an additional 12,951 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new position in shares of Omeros during the 1st quarter worth $85,000. Comerica Bank boosted its position in shares of Omeros by 20.0% during the 1st quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 5,000 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Omeros by 2.6% in the first quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock valued at $11,213,000 after purchasing an additional 81,348 shares during the period. 48.79% of the stock is owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.